Metabolic landscape remodeling in dystrophic muscle through glucocorticoid steroid regimens
Ontology highlight
ABSTRACT: Duchenne muscular dystrophy is caused by genetic defects in the gene encoding dystrophin and leads to progressive muscle degeneration. Glucocorticoid steroids are current mainstay pharmacological regimen to decrease muscle inflammation and prolong the ambulatory period in these patients, but daily intake of glucocorticoids like prednisone and deflazacort causes adverse side effects like osteoporosis, adrenal suppression, insulin resistance and obesity. Intermittent steroid dosing has been proposed as alternative to maintain benefits and limit side effects, but a detailed understanding of the mechanisms underpinning the regimen-specific effects in muscle is still missing. Here we explore how once-daily versus once-weekly prednisone (4 week-long treatment) affect the metabolomic landscape in mdx mouse muscle (genetic model of Duchenne muscular dystrophy; DBA/2J background) through metabolomics profiling.
ORGANISM(S): Mouse Mus Musculus
TISSUE(S): Muscle
DISEASE(S): Muscular Dystrophy
SUBMITTER: Mattia Quattrocelli
PROVIDER: ST001256 | MetabolomicsWorkbench | Thu Sep 26 00:00:00 BST 2019
REPOSITORIES: MetabolomicsWorkbench
ACCESS DATA